A new clinical trial in the North East of England aims to explore improved treatment options for individuals living with bipolar disorder and depression, conditions for which current therapies often present significant side effects. The ASCEnD trial is investigating whether combining the antipsychotic medication aripiprazole with the commonly prescribed antidepressant sertraline can provide effective relief while minimizing adverse effects.
Depression frequently affects people with bipolar disorder, causing symptoms such as persistent sadness, anxiety, difficulty concentrating, loss of interest in activities, and in severe cases, suicidal thoughts. Current treatment options, including the antipsychotic quetiapine, can help manage these symptoms but often lead to issues like persistent drowsiness and weight gain, which may negatively impact patients’ overall quality of life.
Dr. Stuart Watson, a consultant psychiatrist and chief investigator on the study, emphasized the importance of finding better therapeutic alternatives. He noted that a previous smaller-scale trial showed promise for combining aripiprazole with an antidepressant, indicating potential benefits with fewer side effects than existing treatments.
Funded in part by the National Institute for Health and Care Research (NIHR), the ASCEnD trial seeks to build on these early findings by conducting a larger-scale evaluation of the medication combination. The study is currently recruiting participants from the region who are affected by bipolar disorder and depression to determine the treatment’s safety and effectiveness more comprehensively.
Further information about eligibility and enrollment is available through the ASCEnD trial’s official website. The study reflects ongoing efforts to address the complex needs of patients with mental health disorders by advancing evidence-based medical approaches.